Ocugen Inc at H.C. Wainwright BioConnect Investor Conference Transcript
Good morning and thanks for joining us to have a conversation with Shankar Musunuri. He is the Chairman, CEO, and Co-founder of Ocugen. Ocugen is a biotechnology company focusing on discovering, developing, and commercializing novel gene therapies and also vaccines to improve health and offer hope for patients across the globe.
The company's proprietary modifier gene therapy platform has generated numerous clinical candidates and has its lead clinical candidate, OCU400, in the clinic. Management plans to file an IND shortly for its second gene modifier candidate, OCU410, for treating dry age-related macular edema. Additionally, the company is planning to file an IND to initiate a clinical program with its biologic OCU200 for diabetic macular edema as well.
So to discuss the company's ocular therapy platform and also the cell therapy NeoCart and vaccines against COVID-19 virus, let's get started with Shankar.
So, Shankar, I'm glad to see you here and I appreciate you accepting our invitation to talk to our audience
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
